
### Accepted Manuscript

Self-assembled hyaluronic acid-testosterone nanocarriers for delivery of anticancer drugs

Javier Perez Quinones, Johanna Jokinen, Salli Keinänen, Carlos Peniche Covas, Oliver Brüggemann, Dmitri Ossipov

PII:	S0014-3057(17)31870-0
DOI:	https://doi.org/10.1016/j.eurpolymj.2017.12.043
Reference:	ЕРЈ 8230
To appear in:	European Polymer Journal
Received Date:	21 October 2017
Revised Date:	13 December 2017
Accepted Date:	28 December 2017



Please cite this article as: Perez Quinones, J., Jokinen, J., Keinänen, S., Peniche Covas, C., Brüggemann, O., Ossipov, D., Self-assembled hyaluronic acid-testosterone nanocarriers for delivery of anticancer drugs, *European Polymer Journal* (2017), doi: https://doi.org/10.1016/j.eurpolymj.2017.12.043

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Self-assembled hyaluronic acid-testosterone nanocarriers for delivery of anticancer drugs

#### <u>Javier Perez Quinones<sup>a,\*</sup></u>, Johanna Jokinen<sup>b</sup>, Salli Keinänen<sup>b</sup>, Carlos Peniche Covas<sup>c</sup>, Oliver Brüggemann<sup>a</sup>, Dmitri Ossipov<sup>d</sup>

<sup>a</sup> Johannes Kepler University Linz, Institute of Polymer Chemistry, Altenberger Straße 69, 4040 Linz, Austria. javenator@gmail.com; oliver.brueggemann@jku.at
<sup>b</sup> University of Turku, Department of Biochemistry, Vatselankatu 2, 20500 Turku, Finland. johjok@utu.fi; sakakei@utu.fi

<sup>c</sup> University of Havana, Center of Biomaterials, Ave. Universidad s/n entre G y Ronda, Vedado, 10400 La Habana, Cuba. cpeniche2015@yahoo.com

<sup>d</sup> Uppsala University, Department of Chemistry-Angstrom Laboratory, Lägerhyddsvägen 1, Uppsala, SE 751 21, Sweden. dmitri.ossipov@kemi.uu.se

#### Abstract

The present research aims at controlled delivery of anticancer drugs camptothecin and doxorubicin through encapsulation in self-assembled hyaluronic acid (HA)-testosterone coniugates. The conjugates were obtained by functionalization of either natural sodium hyaluronate or hydrazide-modified HA derivatives with testosterone hemisuccinate. From 2.0 to 7.7% of HA disaccharide units were linked to testosterone via two types of linkers of different length. Fourier transform infrared and proton nuclear magnetic resonance spectroscopies confirmed modification of HA. Conjugation of hydrophobic testosterone to hydrophilic backbone of HA resulted in the self-assembly of amphiphilic HA-testosterone conjugates in aqueous medium and the formation of stable and negatively charged nanoparticles with hydrodynamic diameter ranging from 172 to 380 nm and ζ-potential ranging from -37 to -26 mV, as evidenced from dynamic light scattering measurements. Examination of the dried conjugates by transmission electron microscopy revealed almost spherical particles of 50 to 100 nm size. Entrapment of camptothecin and doxorubicin in the hydrophobic core of HA-testosterone nanoparticles was performed with the drugs content of ca. 2.8 wt.% and 3.5 wt.% respectively. The sustained release of the anticancer drugs over 96 h was observed in phosphate buffered saline at pH 7.4. Cytotoxicity of camptothecin- and doxorubicin-loaded HA-testosterone nanoparticles against MCF-7 cancer cell line was found to be similar to the cytotoxicity of the free anticancer drugs. Based on the results of the in vitro studies, we can conclude that the developed HAtestosterone nanoparticles are promising candidates in chemotherapy treatments of cancers.

#### Keywords

Hyaluronic acid; testosterone; anticancer drugs; self-assembled nanoparticles; sustained release.

#### **1. Introduction**

Doxorubicin (DOX) is a traditional anticancer drug widely employed in combination with other chemotherapeutic agents for treatment of some leukemias, lymphomas, and cancers of bladder, stomach, breast, ovaries, lung, thyroid and multiple myeloma. However, high therapeutic doses of DOX administered over months of clinical tumor treatments raise the incidence of related life threatening side effects such as cardiomyopathy, with subsequent congestive heart failure, myelosuppression and acute bowel infection [1,2]. Another inhibitor of

Download English Version:

## https://daneshyari.com/en/article/7803984

Download Persian Version:

https://daneshyari.com/article/7803984

Daneshyari.com